Gilead Sciences Inc., of Foster City, Calif., said the FDA approved additional indications for hepatitis C virus (HCV) drug Harvoni (ledipasvir/sofosbuvir) for use in patients with genotype 4, 5 and 6 chronic HCV infection and in patients co-infected with HIV.